|
Friday, 02 November 2007 |
|
Corpobligation: Micro credit, micro finance, small holder lending, micro creditos...whatever you call it...micro finance is a big deal and ACCION International is one of the biggest organizations:
- Micro credit organizations have moved past a donor-charity system to a sustainable financial model of helping the poorest of the poor
- Accion International is a pioneer and strong example of the micro credit model's potential
- Micro lending has been more successful in the "developing" world than the "developed" world, but social lending by individuals to other individuals has blossomed on the internet
- Corporate social responsibility stumbling blocks claimed by mainstream banks are challenged by the success of micro finance...
|
|
Read more...
|
|
|
Thursday, 20 September 2007 |
Corpobligation: Quick responses to cistomer complaints may cost in the short term but they can mitigate potential long term costs.
- Zara, a Spanish owned fashion retailer, withdrew a bag with a swastika symbol on it.
The bag was externally sourced, according to Zara's spokesperson.
- This emphasizes the importance of supervising suppliers and quick responses to customers
BBC reports :
- The customer, Rachel Hatton, said, "I was quite shocked - I took it back to the shop."
- "Then obviously the shop assistants were quite shocked as well to find out this symbol was on there - it was not something that they'd noticed either straight away," she told BBC Radio 4's Today programme.
|
|
Read more...
|
|
|
Tuesday, 28 August 2007 |
Corpobligation.com: Battling PR campaigns over the future of drug access, production and patents
- A fight over the patentability of a cancer drug (Glivic, Gleevic, Imatinib) produced by Novartis has led to a wider debate around patents over drugs

- Patents are Good: encourage innovation and risk taking, by preserving long term profits
- Patents are Bad: prevent access to drugs because the patent holder charges more than generic drug makes would charge
- Novartis challenged Indian patent law for failing to provide sufficient protection from the competition under WTO rules
- Groups like Medicins Sans Frontieres (Doctors without Borders) disagreed arguing that drug access was vital for worldwide health, especially in developing countries
- Corporate Obligation? Did Novartis do the right thing strategically? They donate many treatments in India (99% according to their site) of Glivic and they have been upfront with their position; yet, a worldwide coalition formed to attack them. How can NGOs and governments create incentives to drive drug innovation?
|
|
Read more...
|
|
|